ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1622

Deep-Sequencing Reveals Class-Specific Urinary Micrornas In Human Lupus Nephritis

Beatrice Goilav1, Iddo Z. Ben-Dov2, Irene Blanco3, Olivier Loudig4, Dawn M. Wahezi5 and Chaim Putterman6, 1Division of Nephrology, Children's Hospital at Montefiore, Bronx, NY, 2Laboratory of RNA Molecular Biology, The Rockefeller University, New York, NY, 3Rheumatology, Albert Einstein College of Medicine, Bronx, NY, 4Epidemiology, Albert Einstein College of Medicine, Bronx, NY, 5Pediatric Rheumatology, Children's Hospital Montefiore, Bronx, NY, 6Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: MicroRNA, Urinary Biomarkers and lupus nephritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus-Human Etiology and Pathogenesis: Genetics and Genomics

Session Type: Abstract Submissions (ACR)

Background/Purpose: Lupus nephritis (LN), particularly, ISN/RPS class IV LN, is associated with significant morbidity and mortality. microRNAs (miRs) are small, non-coding RNAs that regulate translation. Previous studies report changes in miR expression in kidney tissue, urine and PBMCs that correlate with LN disease activity. However, LN class-specific miRs have not been previously described.

Using deep-sequencing, we aimed to identify class-specific miRs in urine from adult and pediatric patients with biopsy-proven LN.

Methods: Cell-free urine from adult (n=25) and pediatric (n=8) female patients with ISN/RPS class III, IV (proliferative) and class V LN were obtained at time of active disease and during remission. Total RNA was used to prepare small RNA cDNA libraries for sequencing. Multiplexing through sample-specific 3′ adapters was applied to limit batch effects and cost. Sequence reads were mapped to the human genome and small RNA databases. miRs were quantified by relative read abundance. qRT-PCR was used for quantitative validation.

Results: We had specimens from adult patients with distinct class III, IV, and V LN and pediatric patients with class III and IV. Samples from pediatric patients with class V LN were mixed with another class LN. We obtained reproducible miR profiles. In a paired-sample analysis we compared miR abundance in adult and pediatric active vs inactive LN, proliferative vs non-proliferative LN, class IV vs class III LN, active class III vs inactive class III LN, active class IV vs inactive class IV LN, and adult active class V vs inactive class V LN. In this analysis, we found significant changes in miR-324, -320, -200c (adult), -375 (pediatric), -200c, -30a, and -671*, respectively. All changes had a p value of <0.001, except for miR-30a (p=0.0011). Changes in miR abundance ranged from -11.8-log fold change to 11.3-log fold change.

Conclusion: In this study, we detected significant changes in miR abundance related to specific LN classes. Given that the prognosis of class IV LN is significantly worse than that of class III, identifying miRs that are associated with class IV LN is an important step in biomarker discovery of this particular aggressive form of LN. Identification of target genes of these miRs may open a venue for the discovery of new pathogenic pathways in this devastating disease.


Disclosure:

B. Goilav,
None;

I. Z. Ben-Dov,
None;

I. Blanco,
None;

O. Loudig,
None;

D. M. Wahezi,

GlaxoSmithKline,

2,

Pfizer Inc,

2;

C. Putterman,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/deep-sequencing-reveals-class-specific-urinary-micrornas-in-human-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology